Sangamo Biosciences Inc (SGMO)

[randallmcm]

Re: Monogenetic disorders and their potential...
Will big Pharma partner number two wait until the proof of concept announcement that will be made by Shire in the not too distant future???? When the upfront fee increases to $13 Million per target gene or will they sign with Sangamo prior to shires next announcement?

When will these gene targets receive a partner???

Hemoglobinopathies(SCA, B-thalassemia)

Immune System Disorders (X-SCID, ADA-SCID, W-A)

EL indicated that partnerships are the stated path of advancing progress on gene targets beyond the current capabilities of their own staff... Will the above be Sangamo targets or targets of Big Pharma Partnerships... How many different partnerships are available to Sangamo in the treatment of monogenetic diseases.

Many, many perhaps too many to imagine...

I posted a cash flow analysis of Sangamo with six pharma partnerships comparable to Shire thru 2021 and a projected share price of $320...

Will future partnerships be as inexpensive to Big Pharma as Shire's deal... I don't think so... Sangamo will drive research until the financial benefits to Sangamo are at a higher inflection ratio than the Shire deal and these partnerships will be more beneficial not less.

JMHO,

RM